Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00886821 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
NCT00886821: Completed Phase 1 study, sponsored by Pfizer.
NCT00886821 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 114 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00886821, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
Primary Outcome
AUClast was defined as area under the concentration-time curve from time zero to the time of last measured concentration and calculated by using linear up/log down trapezoidal method.
Interventions
- BIOLOGICAL CVX-096
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
What the finished NCT00886821 record still lists
NCT00886821 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% higher).
The record links to 0 conditions, and to 1 intervention - of which CVX-096 is the first listed.
NCT00886821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00886821 about?
NCT00886821 is a clinical study titled "A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics". The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
What is the current status of trial NCT00886821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2008-10. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00886821?
The interventions under investigation include: CVX-096 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00886821?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00886821's enrollment target sits among peer trials
114 507th of 2000 higher than 1,493 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia